491 / 1498
BCR signature:
–
SYK
–
PI3K: idelalisib
–
PKC-β: enzastaurin
–
BTK: ibrutinib
–
PKi: dasatinib
–
mTOR: everolimus
BCL6 inhibitors
Proteasome inhibitors
Apoptosis: ABT-199
IMIDS: lenalidomide
Others
New treatment targeted modalities
Target signaling pathways